117235-22-0

Basic information

• Product Name: (5-Bromo-1H-indol-3-yl)-acetic acid methyl ester
• Synonyms: (5-Bromo-1H-indol-3-yl)-acetic acid methyl ester;methyl 2-(5-bromo-1H-indol-3-yl)acetate;Methyl 5-Bromoindole-3-acetate
• CAS NO: 117235-22-0
• Molecular Formula: C₁₁H₁₀BrNO₂
• Molecular Weight: 268.1066
• Mol File: 117235-22-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 394.1±27.0 °C(Predicted)
• Appearance: /
• Density: 1.569±0.06 g/cm3(Predicted)
• PKA: 15.70±0.30(Predicted)
• CAS DataBase Reference: (5-Bromo-1H-indol-3-yl)-acetic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (5-Bromo-1H-indol-3-yl)-acetic acid methyl ester(117235-22-0)
• EPA Substance Registry System: (5-Bromo-1H-indol-3-yl)-acetic acid methyl ester(117235-22-0)

Safety Data

• Hazardous Substances Data: 117235-22-0(Hazardous Substances Data)

Usage

General Description

The chemical compound "(5-Bromo-1H-indol-3-yl)-acetic acid methyl ester" is a methyl ester derivative of 5-bromoindole-3-acetic acid. It is an indole derivative that contains a bromine atom and a methyl ester functional group. (5-Bromo-1H-indol-3-yl)-acetic acid methyl ester has potential applications in the field of organic synthesis, pharmaceuticals, and agrochemicals. It may have biological activity as a plant growth regulator or hormone, as well as potential therapeutic uses in the treatment of various diseases. Additionally, it can serve as a versatile building block for the synthesis of more complex organic molecules. Overall, "(5-Bromo-1H-indol-3-yl)-acetic acid methyl ester" is a valuable chemical compound with diverse potential applications in various scientific and industrial fields.

Upstream product

• 774-14-1 (5-bromo-1H-indol-3-yl)-acetonitrile 
• 830-93-3 N-[(5-bromo-1H-indol-3-yl)methyl]-N,N-dimethylamine 
• 10075-50-0 5-bromo-1H-indole 
• 75-77-4 chloro-trimethyl-silane 
• 40432-84-6 (5-bromo-1H-indol-3-yl)-acetic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 

Downstream Products

• 1334298-70-2 methyl 2-(1-methyl-5-phenyl-1H-indol-3-yl)acetate 
• 1334298-34-8 2-(1-methyl-5-phenyl-1H-indol-3-yl)ethanol 
• 1334298-71-3 methyl 2-(5-mesityl-1-methyl-1H-indol-3-yl)acetate 
• 1334298-35-9 2-(5-mesityl-1-methyl-1H-indol-3-yl)ethanol 
• 1368633-66-2 C₁₇H₁₅NO₂ 
• 1334298-76-8 2-(1-methyl-5-phenyl-1H-indol-3-yl)-N-tosylacetamide 
• 1334298-38-2 4-methyl-N-(2-(1-methyl-5-phenyl-1H-indol-3-yl)ethyl)benzenesulfonamide 
• 1334298-77-9 2-(5-mesityl-1-methyl-1H-indol-3-yl)-N-tosylacetamide 
• 1334298-39-3 N-(2-(5-mesityl-1-methyl-1H-indol-3-yl)ethyl)-4-methylbenzenesulfonamide 
• 1334298-55-3 3a-fluoro-5-mesityl-8-methyl-1-tosyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole 
• 142273-20-9 kenpaullone 

Relevant articles and documents

ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF

The present invention relates to heterocyclic compounds of Formula F-I useful as anti-infective agents. The present invention further relates to a method of treating an infection by administering such compounds, and to pharmaceutical compositions comprising such compounds.

New synthetic approach to paullones and characterization of their SIRT1 inhibitory activity

A series of 7,12-dihydroindolo[3,2-d][1]benzazepine-6(5H)-ones (paullones) substituted at C9/C10 (Br) and C2 (Me, CF3, CO2Me) have been synthesized by a one-pot Suzuki-Miyaura cross-coupling of an o-aminoarylboronic acid and methyl 2-iodoindoleacetate followed by intramolecular amide formation. Other approaches to the paullone scaffold based on Pd-catalyzed C-H activation were unsuccessful. In vitro enzymatic assay with recombinant human SIRT-1 indicated a strong inhibitory profile for the series, in particular the analogue with a methoxycarbonyl group at C2 and a bromine at C9. These compounds are, in general, inducers of granulocyte differentiation of the U937 acute leukemia cell line and cause a marked increase in pre-G1 of the cell cycle.

SMALL MOLECULE INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE WITH POTENTIAL ANTICANCER ACTIVITY

The present invention generally relates to inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt), in particularly to compounds that inhibit Icmt activity and pharmaceutical compositions thereof. The invention also relates to methods of disease treatment using the same.